CA03783R1073

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

 US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase…

16 hours ago